Your browser doesn't support javascript.
loading
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni, Gavin; Kappos, Ludwig; de Seze, Jerome; Hauser, Stephen L; Overell, James; Koendgen, Harold; Manfrini, Marianna; Wang, Qing; Wolinsky, Jerry S.
Afiliación
  • Giovannoni G; Queen Mary University of London, London, UK.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience and MS Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • de Seze J; University Hospital of Strasbourg, Strasbourg, France.
  • Hauser SL; University of California, San Francisco, CA, USA.
  • Overell J; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Koendgen H; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Manfrini M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Wang Q; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Eur J Neurol ; 29(4): 1238-1242, 2022 04.
Article en En | MEDLINE | ID: mdl-33724637
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido